Gino Van Heeke
Gino Van Heeke (Ablynx) joined Ciba Pharmaceuticals in Basle, Switzerland, in the Department of Molecular Biology, Biotechnology, in 1992. He held various positions in the company including Group Leader and Project Team Leader. In 1995, he moved to the research center in Horsham, UK, as Head of Molecular and Cell Biology. In 1997, the company merged with Sandoz to form Novartis, where he became first Director of Biology and later Executive Director Biotherapeutics for the Respiratory Disease Area. He is currently Senior Director, Discovery and Early Development Project Management at Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments. Dr. Van Heeke holds a degree in biochemical engineering from the University of Ghent and a PhD in biochemistry from the University of Nebraska, Lincoln.